KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $7.5 billion.

  • Abbott Laboratories' Cash & Equivalents fell 62.19% to $7.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 billion, marking a year-over-year decrease of 62.19%. This contributed to the annual value of $7.6 billion for FY2024, which is 1044.08% up from last year.
  • As of Q3 2025, Abbott Laboratories' Cash & Equivalents stood at $7.5 billion, which was down 62.19% from $7.0 billion recorded in Q2 2025.
  • Over the past 5 years, Abbott Laboratories' Cash & Equivalents peaked at $9.9 billion during Q4 2022, and registered a low of $6.3 billion during Q1 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $7.7 billion (2022), whereas its average is $8.0 billion.
  • In the last 5 years, Abbott Laboratories' Cash & Equivalents skyrocketed by 13849.57% in 2021 and then crashed by 3140.49% in 2024.
  • Over the past 5 years, Abbott Laboratories' Cash & Equivalents (Quarter) stood at $9.8 billion in 2021, then increased by 0.85% to $9.9 billion in 2022, then plummeted by 30.22% to $6.9 billion in 2023, then grew by 10.44% to $7.6 billion in 2024, then dropped by 1.38% to $7.5 billion in 2025.
  • Its Cash & Equivalents stands at $7.5 billion for Q3 2025, versus $7.0 billion for Q2 2025 and $6.5 billion for Q1 2025.